🔗 Share this article The Global Health Body Issues Concern Over Acute Scarcity of Weight-Loss Jabs Fewer than one in 10 individuals who could benefit from weight-loss injections including Wegovy can access them, caution the World Health Organization as it publishes its inaugural guidance on the medications. Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging broader and more equitable access to this class of drugs. Based on forecasts, over two billion are projected to be obese by 2030 without intervention. "The latest guidelines acknowledges that obesity is a chronic disease that can be treated with comprehensive and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major hurdles to universal access to the jabs that can aid individuals in losing considerable weight, says the organization. Weight-Loss Drug Supply Crisis Even in the present most optimistic case, the production of such drugs might only reach about 100 million people – less than 10% of those who need them, per the health organization. The advice urges countries and companies to widen availability, through strategies like patent sharing. A patent on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026. How Weight-Loss Jabs Function GLP-1 drugs replicate a natural hormone to reduce digestion speed, suppress the appetite and boost feelings of fullness so people consume fewer calories. Individuals typically begin shedding pounds after several weeks of beginning the regular doses. Evidence points to users may put most of the weight back on within a year of discontinuing the drug, when their typical appetite return. Being carrying excess weight elevates your risk for contracting diseases, including diabetes, cardiovascular issues, stroke, and some cancers. Excess weight impacts people in every country and was responsible for millions of deaths worldwide in 2024, as per the health agency.
Fewer than one in 10 individuals who could benefit from weight-loss injections including Wegovy can access them, caution the World Health Organization as it publishes its inaugural guidance on the medications. Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging broader and more equitable access to this class of drugs. Based on forecasts, over two billion are projected to be obese by 2030 without intervention. "The latest guidelines acknowledges that obesity is a chronic disease that can be treated with comprehensive and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major hurdles to universal access to the jabs that can aid individuals in losing considerable weight, says the organization. Weight-Loss Drug Supply Crisis Even in the present most optimistic case, the production of such drugs might only reach about 100 million people – less than 10% of those who need them, per the health organization. The advice urges countries and companies to widen availability, through strategies like patent sharing. A patent on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026. How Weight-Loss Jabs Function GLP-1 drugs replicate a natural hormone to reduce digestion speed, suppress the appetite and boost feelings of fullness so people consume fewer calories. Individuals typically begin shedding pounds after several weeks of beginning the regular doses. Evidence points to users may put most of the weight back on within a year of discontinuing the drug, when their typical appetite return. Being carrying excess weight elevates your risk for contracting diseases, including diabetes, cardiovascular issues, stroke, and some cancers. Excess weight impacts people in every country and was responsible for millions of deaths worldwide in 2024, as per the health agency.